

Miguel Ángel MacÃ-as Islas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5083244/publications.pdf>

Version: 2024-02-01

22
papers

998
citations

759233

12
h-index

677142

22
g-index

24
all docs

24
docs citations

24
times ranked

1679
citing authors

#	ARTICLE	IF	CITATIONS
1	Polymorphisms CYP2R1 rs10766197 and CYP27B1 rs10877012 in Multiple Sclerosis: A Case-Control Study. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	2.2	4
2	Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview. <i>Biomedicines</i> , 2019, 7, 22.	3.2	75
3	Low levels of alpha-synuclein in peripheral tissues are related to clinical relapse in relapsing-remitting multiple sclerosis: a pilot cross-sectional study. <i>Journal of the Neurological Sciences</i> , 2019, 396, 87-93.	0.6	4
4	Mediational Model of Multiple Sclerosis Impairments, Family Needs, and Caregiver Mental Health in Guadalajara, Mexico. <i>Behavioural Neurology</i> , 2018, 2018, 1-11.	2.1	7
5	Mental Health and Health-Related Quality of Life in Multiple Sclerosis Caregivers in Mexico. <i>International Journal of MS Care</i> , 2016, 18, 19-26.	1.0	10
6	Biological and nonbiological complex drugs for multiple sclerosis in Latin America: regulations and risk management. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 597-600.	2.8	7
7	Novel Point Mutations and A8027G Polymorphism in Mitochondrial-DNA-Encoded Cytochrome c Oxidase II Gene in Mexican Patients with Probable Alzheimer Disease. <i>International Journal of Alzheimer's Disease</i> , 2014, 2014, 1-5.	2.0	5
8	Role of the Blood-Brain Barrier in Multiple Sclerosis. <i>Archives of Medical Research</i> , 2014, 45, 687-697.	3.3	261
9	A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. <i>Journal of Neurology</i> , 2014, 261, 2101-2111.	3.6	34
10	Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease. <i>Human Brain Mapping</i> , 2013, 34, 3308-3319.	3.6	13
11	Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. <i>Acta Neurologica Belgica</i> , 2013, 113, 415-420.	1.1	6
12	The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review. <i>Multiple Sclerosis Journal</i> , 2013, 19, 844-854.	3.0	62
13	The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 154-159.	1.4	72
14	Immunology and Oxidative Stress in Multiple Sclerosis: Clinical and Basic Approach. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-14.	3.3	144
15	Increased fMRI signal with age in familial Alzheimer's disease mutation carriers. <i>Neurobiology of Aging</i> , 2012, 33, 424.e11-424.e21.	3.1	17
16	Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 799-806.	0.8	7
17	Oxidative Stress is Increased in Serum from Mexican Patients with Relapsing-Remitting Multiple Sclerosis. <i>Disease Markers</i> , 2009, 26, 35-39.	1.3	48
18	Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. <i>Disease Markers</i> , 2009, 26, 35-9.	1.3	30

#	ARTICLE	IF	CITATIONS
19	Performance on MMSE sub-items and education level in presenilin-1 mutation carriers without dementia. <i>International Psychogeriatrics</i> , 2007, 19, 323.	1.0	7
20	The A431E mutation in PSEN1 causing Familial Alzheimer's Disease originating in Jalisco State, Mexico: an additional fifteen families. <i>Neurogenetics</i> , 2006, 7, 277-279.	1.4	62
21	Prevalence of Migraine in Latin America. <i>Headache</i> , 2005, 45, 106-117.	3.9	76
22	Clinical Characteristics and Patterns of Medication Use of Migraneurs in Latin America From 12 Cities in 6 Countries. <i>Headache</i> , 2005, 45, 118-126.	3.9	46